What do you speculate might be the most important mechanistic explanations for the reduction in CV events reported with liraglutide in the LEADER trial?

What do you speculate might be the most important mechanistic explanations for the reduction in CV events reported with liraglutide in the LEADER trial?

What do you speculate might be the most important mechanistic explanations for the reduction in CV events reported with liraglutide in the LEADER trial?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Juan Frias, FACE, MD

Juan Frias, FACE, MD

Clinical Assistant Professor of Medicine
University of California
San Diego, California
Chief Medical Officer
National Research Institute
Los Angeles, California